DEMONSTRATION OF ANTIGENIC AND SPECIFIC OUTER MEMBRANE PROTEIN(S) OF \textit{Acinetobacter baumannii}

A. H. M. SHAFIQUL ISLAM

UNIVERSITI SAINS MALAYSIA

2009
DEMONSTRATION OF ANTIGENIC AND SPECIFIC OUTER MEMBRANE PROTEIN(S) OF *Acinetobacter baumannii*

by

A. H. M. SHAFIQUL ISLAM

Thesis submitted in fulfillment of the requirements for the degree of Master of Science

June 2009
ACKNOWLEDGEMENTS

First and foremost I bend over with gratefulness to Almighty Allah, the merciful and beneficent- without his kind blessings nothing is possible.

I would like to express my wholehearted thanks to my supervisor Professor Asma Ismail, who meticulously with care and attention, advised me and motivated me to produce the final product. Without her untiring and patient supervision, the thesis would never have been completed in a satisfactory manner. I am indebted to her for the immense trust and patience she had in me and training me right from the very beginning to the level where I am now.

I would like to acknowledge my co-supervisor, Dr. Kirnpal Kaur Banga Singh for her constant support encouragement and guidance throughout my study. Her command on the subject and her excellent communication skills made it easier for me to analyse and present the results and discuss on it.

I also express my heartfelt gratitude to Professor Prabha Balaram for her encouragement and support in the pursuit of my study and aspiration. I am grateful for her constructive criticism during the preparation of the draft and her guidance and advice at time of difficulty.

I would like to profusely thank Dr. Azian Harun and Dr. Zakuan Zainy bin Deris, lecturers at Department of Medical Microbiology and Parasitology, PPSP for their help
during the initial stages of my work and providing me the necessary data related to my work. I am grateful to Mr. Mohd. Nadzri Abu Yazid, Mrs. Rosliza Abd. Rahman, Mrs. Rosni bt. Wan Yakob, Mrs. Fadzilah Ahmad and Mrs. Noor Asmaliza bt. Abdullah for their worthy help during the collection of my samples.

I offer my unconditional thanks to my best friend Mr. Thiruchelvan Nadarajan who helped me to learn molecular techniques from scratch and sort out technical problems during optimization. I would like to express my appreciation to Mr. Zafri bin Muhammad for his technical advice and kindness that allowed me to educate myself in required computer handling.

I am grateful to all proteomic, genomic and MBDr lab members of INFORMM for their kind encouragement and support in the pursuit of my studies with special thanks to Mrs. Aziah Ismail and Mrs. Che Nur Anini bt. Awang. My sincere appreciation is also to Mrs. Noral Wiah Haji Abdul Karim and all the administrative staff of INFORMM for their cooperation and support during the tenure of my study. I also extend my gratitude to all the students and staff of INFORMM, some of whom are very good friends of mine.

Deep from my heart with love and faith, I would like to thank my beloved parents and my elder brother A. K. M. Tariqul Islam for their constant encouragement and blessings throughout my life that assisted me to prevail upon this study. My gratefulness to my wife Mrs. Farah Deeba and my son Master Farhan Sadik for their support and patience, which saw me through this study. Their endless love and patience energized me to finish this thesis. Last but not the least, my thankfulness to many other
friends whom I might have failed to mention here, but need to be acknowledged for their
direct or indirect support in some way or other to complete this thesis.

This study was financially supported by RU Grant No. 1001/CIPPM/8130131
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>ii</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>v</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>xii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>xiv</td>
</tr>
<tr>
<td>LIST OF ABBREVIATION AND SYMBOLS</td>
<td>xv</td>
</tr>
<tr>
<td>ABSTRAK</td>
<td>xvi</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>xix</td>
</tr>
</tbody>
</table>

## CHAPTER ONE: INTRODUCTION

1.0 Introduction

1.1 History and significance of *Acinetobacter baumannii* infection

1.1.1 Epidemiology

1.1.2 Classification/taxonomy

1.1.3 Properties of *Acinetobacter baumannii*

1.1.3.1 Physical characteristics

1.1.3.2 Growth and cultural characteristics

1.1.3.3 Biochemical characteristics

1.1.3.4 Physiology and morphology
1.2 Clinical significance of *Acinetobacter baumannii*

1.2.1 Pathogenesis

1.2.2 Virulence factors

1.2.3 Risk factors

1.2.4 Prevalence

1.2.5 Antimicrobial susceptibility and resistant mechanisms

1.2.6 Treatment

1.3 Rationale of the study

1.4 Objective of the study

**CHAPTER TWO : MATERIALS AND METHODS**

2.1 Materials

2.1.1 Bacteria

2.1.2 Growth and maintenance of bacterial strains

2.1.3 Sera samples

2.1.3.1 Western Blot

2.1.4 Chemicals and Media

2.1.4.1 Media

2.1.4.1.1 Blood Agar

2.1.4.1.2 MacConkey Agar

2.1.4.1.3 Nutrient Broth

2.1.4.1.4 Tryptic Soy Broth (TSB) with 10% Glycerol

2.1.4.2 Preparation of common buffers and reagents

2.1.4.2.1 Phosphate Buffered Saline (PBS)

2.1.4.2.2 HEPES Buffer (pH 7.4)

2.1.4.2.3 Tris-HCl 30 mM (pH 8.0)

2.1.4.2.4 Tris-HCl 10 mM (pH 7.4)

2.1.4.2.5 0.2 M Glycine-HCl (pH 2.2)

2.1.4.2.6 3 M NaOH
2.1.4.2.7  Lysozyme Solution (10 mg/ml)  31
2.1.4.2.8  Phenylmethylsulphonyl fluoride (PMSF)  31
2.1.4.2.9  Normal Saline 0.9 %  31
2.1.4.2.10  Acetic acid 3 %  32
2.1.4.2.11  Methanol 50 %  32

2.1.4.3  Preparation of reagents for SDS-PAGE  32
2.1.4.3.1  Resolving Gel Buffer, pH 9.3  32
2.1.4.3.2  Stacking Gel Buffer, pH 6.8  33
2.1.4.3.3  Ammonium Persulphate (AP), 20%  33
2.1.4.3.4  Sample Buffer  33
2.1.4.3.5  Running Buffer  33
2.1.4.3.6  Coomassie Blue Stain  34
2.1.4.3.7  Coomassie Destaining Solution  34

2.1.4.4  Preparation of reagents for immunodetection  34
2.1.4.4.1  Western Blot Transfer Buffer  34
2.1.4.4.2  Ponceau S Stain  34
2.1.4.4.3  Blocking Solution, 5%  34
2.1.4.4.4  Washing Buffer PBS-Tween 20 (0.1%)  35

2.2  Methods  35
2.2.1  Outer membrane protein (OMPs) and inner membrane protein (IMPs) preparation  35
2.2.2  Surface associated protein (SAPs) preparation  36
2.2.3  Determination of protein concentration  37
2.2.4  Protein analysis by SDS-PAGE  37
2.2.5  Determination of immunogenicity of the expressed protein  39
2.2.5.1  Electrophoretic transfer of proteins to support membrane  39
CHAPTER THREE : ANALYSIS OF PROTEIN PROFILE OF OUTER MEMBRANE PROTEINS (OMPs) OF Acinetobacter baumannii AND THE INFLUENCE OF TEMPERATURE ON THEIR EXPRESSION

3.0 Introduction 43
3.1 Materials and methods 44
  3.1.1 Bacterial strains 44
  3.1.2 Cell culture and growth condition 44
  3.1.3 Cell envelope preparation of *A. baumannii* culture 45
  3.1.4 Isolation of outer membranes and inner membranes 46
  3.1.5 Determination of protein concentration 47
  3.1.6 Sample preparation 47
  3.1.7 SDS-PAGE 47
  3.1.8 Coomassie Brilliant Blue staining 48

3.2 Results 49
  3.2.1 Optimization of the OMPs concentration for SDS-PAGE 49
  3.2.2 The OMP profiles of ATCC and the clinical isolate expressed at 37°C 49
  3.2.3 The OMP profiles of ATCC and the clinical isolate expressed at 41°C 49
  3.2.4 Comparison of expression of OMPs profile in *Acinetobacter baumannii* ATCC 19606 and the clinical isolate AB 001 at 37°C and 41°C 55
  3.2.4.1 Common OMPs and their expression 55
CHAPTER FOUR: IMMUNOGENIC PROFILE OF OUTER MEMBRANE PROTEINS (OMPs) OF Acinetobacter baumannii

4.0 Introduction

4.1 Materials and methods

4.1.1 Bacterial strains

4.1.2 Sera samples

4.1.2.1 A. baumannii sera

4.1.2.2 Non A. baumannii sera

4.1.2.3 Control sera

4.1.2.4 Immunoglobulin M (IgM) antibodies

4.1.2.5 Immunoglobulin A (IgA) antibodies

4.1.2.6 Immunoglobulin G (IgG) antibodies

4.1.3 Cell culture

4.1.4 OMPs preparation

4.1.5 Determination of protein concentration

4.1.6 Sample preparation

4.1.7 Antigenic determination of OMPs

4.1.7.1 SDS-PAGE

4.1.7.2 Electrophoretic transfer

4.1.7.3 Immunoblotting

4.1.8 Dot EIA analysis

4.1.8.1 Determination of total immunoglobulin in patients’ sera by dot EIA

4.1.8.2 Determination of specific antibodies against OMPs of Acinetobacter baumannii by dot EIA

4.2 Results
4.2.1 Result of dot EIA analysis of sera  
4.2.2 Determination of presence of antibodies against OMPs of *Acinetobacter baumannii* by dot EIA  
4.2.3 Immunoblotting

4.3 Discussion

CHAPTER FIVE: CHARACTERIZATION OF THE SPECIFIC AND ANTIGENIC OUTER MEMBRANE PROTEIN (OMP) OF *Acinetobacter baumannii*

5.0 Introduction  
5.1 Materials and methods  
5.1.1 Growth and maintenance of Bacterial strains  
5.1.2 OMPs and IMPS preparation  
5.1.3 Surface associated protein (SAPs) preparation  
5.1.4 Determination of protein concentration  
5.1.5 Low molecular weight marker  
5.1.6 Confirmation of the location of the specific protein  
5.1.6.1 Coomassie Brilliant Blue staining  
5.1.6.2 Protein analysis by SDS-PAGE  
5.1.7 Confirmation of the chemical nature of the specific protein  
5.1.7.1 Glycoprotein staining  
5.1.7.2 Trypsin digestion

5.2 Results  
5.2.1 Location of the specific protein  
5.2.2 Chemical composition of the specific protein  
5.2.3 Type of the specific protein

5.3 Discussion
## LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>List of the clinical isolates of <em>A. baumannii</em> used in this study</td>
<td>24</td>
</tr>
<tr>
<td>2.2</td>
<td>List of the sera samples used in this study</td>
<td>26</td>
</tr>
<tr>
<td>2.3</td>
<td>List of chemicals, reagents and media used in this study</td>
<td>27</td>
</tr>
<tr>
<td>2.3</td>
<td>List of chemicals, reagents and media used in this study (continued)</td>
<td>28</td>
</tr>
<tr>
<td>3.1</td>
<td>The protein bands of <em>A. baumannii</em> expressed at 37°C</td>
<td>52</td>
</tr>
<tr>
<td>3.2</td>
<td>The protein bands of <em>A. baumannii</em> expressed at 41°C</td>
<td>54</td>
</tr>
<tr>
<td>3.3</td>
<td>Overall expressions of OMPs present in <em>A. baumannii</em> ATCC 19606 and the clinical isolate AB 001 at 37°C and 41°C</td>
<td>57</td>
</tr>
<tr>
<td>3.4</td>
<td>The expression of OMPs in ATCC strain and clinical isolate AB 001 of <em>A. baumannii</em> at 41°C in comparison to that at 37°C</td>
<td>58</td>
</tr>
<tr>
<td>4.1</td>
<td>List of sera used for immunoglobulin profiles analysis of patients’ sera (neat)</td>
<td>66</td>
</tr>
<tr>
<td>4.2</td>
<td>Analysis of immunoglobulin profiles of patients’ sera (neat) by dot EIA probed with anti-human IgM/IgA/IgG</td>
<td>76</td>
</tr>
<tr>
<td>4.3</td>
<td>Analysis of immunoglobulin profiles of patients’ sera (1:100 dilutions) by dot EIA probed with anti-human IgM/IgA/IgG</td>
<td>78</td>
</tr>
<tr>
<td>4.4</td>
<td>Summary of the immunoglobulin level of patients’ sera (both neat &amp; 1:100 dilutions) probed with anti-human IgM/IgA/IgG</td>
<td>79</td>
</tr>
<tr>
<td>4.5</td>
<td>Result of dot EIA profile of <em>A. baumannii</em> OMPs and the clinical isolate AB 001</td>
<td>83</td>
</tr>
<tr>
<td>4.6</td>
<td>Summary of total immunoglobulin and specific immunoglobulin against OMPs of <em>A. baumannii</em> in patients’ sera (both 1:100 dilutions) probed with anti-human IgM/IgA/IgG</td>
<td>84</td>
</tr>
<tr>
<td>4.7</td>
<td>Candidate sera (AB 009 and AB 012) selected for Western blot analysis</td>
<td>86</td>
</tr>
<tr>
<td>4.8</td>
<td>Immunogenic bands of ATCC using patient’s serum AB 009 when probed with anti human IgM, IgA and IgG</td>
<td>91</td>
</tr>
</tbody>
</table>
4.9 Immunogenic bands of ATCC using patient’s serum AB 012 when probed with anti human IgM, IgA and IgG

4.10 Comparison of immunogenic bands of ATCC using patients’ sera AB 009 and AB 012 when probed with anti human IgM, IgA and IgG

4.11 Summary of the immunogenic bands of sera AB 009 and AB 012 when probed with anti-human IgM during Western blot analysis

4.12 Summary of the immunogenic bands of sera AB 009 and AB 012 when probed with anti-human IgA during Western blot analysis

4.13 Summary of the immunogenic bands of sera AB 009 and AB 012 when probed with anti-human IgG during Western blot analysis

5.1 The expression of OMPs in ATCC strain and clinical isolates of *A. baumannii* at 41°C in comparison to that at 37°C
### LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1</td>
<td>OMPs profile of <em>A. baumannii</em> ATCC 19606 expressed at 37°C by SDS-PAGE using different concentrations of OMPs</td>
<td>50</td>
</tr>
<tr>
<td>3.2</td>
<td>OMPs profile of <em>A. baumannii</em> ATCC 19606 and the clinical isolate AB 001 expressed at 37°C using SDS-PAGE</td>
<td>51</td>
</tr>
<tr>
<td>3.3</td>
<td>OMPs profile of <em>A. baumannii</em> ATCC 19606 and the clinical isolate AB 001 expressed at 41°C using SDS-PAGE</td>
<td>53</td>
</tr>
<tr>
<td>3.4</td>
<td>OMPs profile of <em>A. baumannii</em> ATCC 19606 and the clinical isolate AB 001 at 37°C and 41°C</td>
<td>56</td>
</tr>
<tr>
<td>4.1</td>
<td>Immunoglobulin profiles analysis of patients’ sera (neat) by dot EIA probed with anti-human IgM/IgA/IgG</td>
<td>75</td>
</tr>
<tr>
<td>4.2</td>
<td>Immunoglobulin profiles analysis of patients’ diluted sera (1:100) probed with anti-human IgM/IgA/IgG</td>
<td>77</td>
</tr>
<tr>
<td>4.3</td>
<td>Dot EIA result of OMPs (ATCC and the clinical isolate AB 001) expressed at 37°C probed with <em>A. baumannii</em> and other related infections patients’ sera</td>
<td>80</td>
</tr>
<tr>
<td>4.4</td>
<td>Western blotting result of OMPs of <em>A. baumannii</em> probed with anti-human IgM</td>
<td>88</td>
</tr>
<tr>
<td>4.5</td>
<td>Western blotting result of OMPs of <em>A. baumannii</em> probed with anti-human IgA</td>
<td>89</td>
</tr>
<tr>
<td>4.6</td>
<td>Western blotting result of OMPs of <em>A. baumannii</em> probed with anti-human IgG</td>
<td>90</td>
</tr>
<tr>
<td>5.1</td>
<td>Location of the specific protein (in SAPs, OMPs and IMPs)</td>
<td>109</td>
</tr>
<tr>
<td>5.2</td>
<td>Expression of specific band (34.4 kDa) in OMPs of clinical isolates of <em>A. baumannii</em></td>
<td>110</td>
</tr>
<tr>
<td>5.2a</td>
<td>Expression of OMPs of clinical isolates of <em>A. baumannii</em> in response to heat (37°C and 41°C)</td>
<td>111</td>
</tr>
<tr>
<td>5.3</td>
<td>Result of the glycoprotein staining</td>
<td>113</td>
</tr>
<tr>
<td>5.4</td>
<td>Result of trypsin digestion test of specific protein</td>
<td>114</td>
</tr>
<tr>
<td>ABBREVIATION</td>
<td>SYMBOL</td>
<td>MEANING</td>
</tr>
<tr>
<td>--------------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>AP</td>
<td></td>
<td>Alkaline Phosphatase</td>
</tr>
<tr>
<td>ATCC</td>
<td></td>
<td>American Type Culture Collection</td>
</tr>
<tr>
<td>BCCM</td>
<td></td>
<td>Belgian Co-ordinated Collections of Microorganisms</td>
</tr>
<tr>
<td>DNase</td>
<td></td>
<td>Deoxyribinuclease</td>
</tr>
<tr>
<td>EIA</td>
<td></td>
<td>Enzyme Immunoassay</td>
</tr>
<tr>
<td>ELISA</td>
<td></td>
<td>Enzyme Linked Immunosorbent Assay</td>
</tr>
<tr>
<td>HRP</td>
<td></td>
<td>Horse Radish Peroxidase</td>
</tr>
<tr>
<td>HUSM</td>
<td></td>
<td>Hospital Universiti Sains Malaysia</td>
</tr>
<tr>
<td>ICT</td>
<td></td>
<td>Immunochromatography</td>
</tr>
<tr>
<td>ICU</td>
<td></td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>IDSA</td>
<td></td>
<td>Infectious Disease Society of America</td>
</tr>
<tr>
<td>IMP</td>
<td></td>
<td>Inner Membrane Protein</td>
</tr>
<tr>
<td>kDa</td>
<td></td>
<td>Kilodalton</td>
</tr>
<tr>
<td>mA</td>
<td></td>
<td>Milliampere</td>
</tr>
<tr>
<td>MDR</td>
<td></td>
<td>Multi Drug Resistant</td>
</tr>
<tr>
<td>MDRAB</td>
<td></td>
<td>Multi Drug Resistant <em>Acinetobacter baumannii</em></td>
</tr>
<tr>
<td>MW</td>
<td></td>
<td>Molecular weight</td>
</tr>
<tr>
<td>NC</td>
<td></td>
<td>Nitrocellulose Membrane</td>
</tr>
<tr>
<td>OD</td>
<td></td>
<td>Optical Density</td>
</tr>
<tr>
<td>OMP</td>
<td></td>
<td>Outer Membrane Protein</td>
</tr>
<tr>
<td>OXA</td>
<td></td>
<td>Oxacillinase</td>
</tr>
<tr>
<td>PAI</td>
<td></td>
<td>Pathogenicity Island</td>
</tr>
<tr>
<td>PBS</td>
<td></td>
<td>Phosphate Buffered Saline</td>
</tr>
<tr>
<td>PPSP</td>
<td></td>
<td>Pusat Pengajian Sains Perubatan</td>
</tr>
<tr>
<td>RNase</td>
<td></td>
<td>Ribonuclease</td>
</tr>
<tr>
<td>SAP</td>
<td></td>
<td>Surface Associated Protein</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td></td>
<td>Sodium-Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis</td>
</tr>
<tr>
<td>TEMED</td>
<td></td>
<td>N,N,N',N'-tetramethylethylenediamine</td>
</tr>
<tr>
<td>USD</td>
<td></td>
<td>United States Dollar</td>
</tr>
<tr>
<td>USM</td>
<td></td>
<td>Universiti Sains Malaysia</td>
</tr>
<tr>
<td>WHO</td>
<td></td>
<td>World Health Organization</td>
</tr>
<tr>
<td>°C</td>
<td></td>
<td>Degree Celcius</td>
</tr>
<tr>
<td>µg</td>
<td></td>
<td>Microgram</td>
</tr>
<tr>
<td>mg</td>
<td></td>
<td>Milligram</td>
</tr>
<tr>
<td>g</td>
<td></td>
<td>Gram</td>
</tr>
<tr>
<td>nM</td>
<td></td>
<td>Nanometer</td>
</tr>
<tr>
<td>A&lt;sub&gt;280&lt;/sub&gt;</td>
<td></td>
<td>Absorbance at 280 nM</td>
</tr>
</tbody>
</table>
DEMONSTRASI KEHADIRAN PROTEIN MEMBRAN LUAR YANG ANTIGENIK DAN SPESIFIK BAGI *Acinetobacter baumannii*

**ABSTRAK**

*Acinetobacter baumannii* dikenali sebagai bakteria penyebab penyakit nosokomial dan kebanyakannya adalah rintang terhadap pelbagai antibiotik. Ianya juga dikenalpasti sebagai penyebab utama kepada morbiditi dan kematian di hospital terutamanya bagi pesakit yang kurang imuniti terhadap penyakit. Diagnosis awal bagi jangkitan yang disebabkan oleh *A. baumannii* adalah strategi penting untuk mengawal jangkitan nosokomial yang disebabkan oleh bakteria ini. Pengenalpastian bakteria ini pada masa kini adalah dengan menggunakan kaedah pengkulturan konvensional dan ujian biokimia yang mengambil masa lebih kurang 2 hingga 7 hari. Oleh sebab itu, ujian yang cepat, sensitif, spesifik dan murah diperlukan untuk pengurusan yang cepat terhadap jangkitan nosokomial ini.

Pembangunan ujian yang spesifik dan sensitif memerlukan *biomarker* yang tidak bertindakbalas silang dengan bakteria lain dan spesifik hanya untuk *A. baumannii*. Oleh itu, tujuan kajian ini dilakukan adalah untuk mengenalpasti kehadiran protein yang spesifik dan antigenik terhadap *A. baumannii* daripada protein membran luar (OMP) yang boleh digunakan untuk membangunkan ujian diagnostik yang cepat dan spesifik. Profil protein daripada strain ATCC and isolat klinikal *A. baumanii* telah didemonstrasi dengan menggunakan teknik SDS-PAGE dan profil protein yang terhasil daripada kedua-dua strain tersebut dibandingkan. Profil protein daripada isolat klinikal didapati mempunyai persamaan lebih kurang 90% dengan strain ATCC. Seterusnya, protein elektroforetogram tersebut diuji dengan analisis blot...
Western yang ditindak balas dengan serum daripada pesakit yang dijangkiti dengan *A. baumannii*. Satu protein OMP yang antigenik dan juga spesifik berberat molekul 34.4 kDa telah dapat dikenalpasti hadir pada kesemua isolat *A. baumannii* yang dikaji dan tidak bertindak balas silang dengan serum daripada pesakit yang dijangkiti dengan pathogen nosokomial lain atau kontrol normal yang diuji. Eksperimen tersebut diulang beberapa kali untuk mengesahkan kepastian tersebut.

Kajian ini juga dijalankan untuk menilaikan kesan peningkatan suhu terhadap pengekspresan protein OMP. Profil protein pada suhu 41°C menunjukkan sebilangan OMP diekspres dengan kuantiti lebih tinggi (17.3, 22.4 and 60.5 kDa), sementara sebahagian protein yang lain menunjukkan penurunan dalam kuantiti protein yang diekspresi. Keputusan ini mengesyorkan bahawa peningkatan suhu badan semasa jangkitan *A. baumannii* mempengaruhi pengekspresan protein bakteria tersebut, kemungkinan sebagai mekanisma pertahanan terhadap suhu tinggi dan juga rintangan terhadap dadah/ubat bagi memastikan bakteria tersebut boleh hidup dan tumbuh dalam badan pesakit.

Keputusan ujian ini juga menunjukkan bahawa protein 34.4 kDa tersebut hadir pada kedua-dua penyediaan OMP dan SAP daripada *A. baumannii* serta bukan sejenis glikoprotein. Antigen 34.4 kDa hadir dalam ke semua isolat klinikal yang diuji dan didapati ia diekspres dengan kuantiti lebih tinggi pada suhu 41°C. Ini mencadangkan bahawa protein ini mempunyai peranan yang penting dalam mekanisma patogenisiti bakteria tersebut. Sehingga kini, tiada kajian yang dilaporkan mengenai protein yang spesifik terhadap *A. baumannii*. Keputusan kajian yang diperolehi adalah memberansangkan dengan penemuan protein 34.4 kDa yang spesifik terhadap *A.
*baumannii* dan boleh digunakan sebagai *biomarker* dalam pembangunan ujian diagnostik yang lebih cepat dan lebih spesifik jika dibandingkan teknik ujian diagnostik yang digunakan pada masa kini. Walau bagaimanapun, kajian lanjutan perlu dilakukan untuk mengukur tahap antibodi terhadap protein tersebut, sensitiviti dan spesifisiti dan tempoh masa antibodi terhadap protein tersebut dapat dikesan di dalam serum pesakit.
DEMONSTRATION OF ANTIGENIC AND SPECIFIC ANTIGENIC AND SPECIFIC OUTER MEMBRANE PROTEIN(S) (OMPs) OF *Acinetobacter baumannii*

**ABSTRACT**

*Acinetobacter baumannii* has been recognized as an emerging nosocomial pathogen and is very often multi-resistant to antibiotics. It has also been identified as an important cause of morbidity and mortality in hospitals, especially among immunocompromised patients. Early diagnosis of infection caused by *A. baumannii* is the major strategy for controlling the nosocomial infection caused by this pathogen. Current identification of this bacteria is by conventional culture method and biochemical tests, which may take about 2 to 7 days to produce results. Hence, there is a need for a new rapid, sensitive, specific and economical test that would allow the rapid management of *nosocomial A. baumannii* infections.

Development of a specific and sensitive diagnostic test requires a biomarker, which does not cross react with other bacteria and is specific only to *A. baumannii*. This formed the aim of this study: to detect the presence of a specific and antigenic biomarker for *A. baumannii* from the outer membrane proteins (OMPs), which can be used for the development of a rapid and specific diagnostic test. — Protein profiles of OMP lysates from the ATCC strain *(Belgium)* and clinical isolates of *A. baumannii* *(Department of Medical Microbiology and Parasitology, School of Medical Sciences, USM)* were
obtained by applying demonstrated using the technique of Sodium Dodecyl Sulfate-Poly-Acrylamide-Gel Electrophoresis (SSDS-PAGE) and the protein profiles were compared. The protein profiles of the clinical isolates were 90% identical to that of the ATCC strain. Following this, the protein electrophoretograms were subjected to Western blot analysis using serum from patients infected with *A. baumannii* and non-*A. baumannii*. The Western blot analysis revealed a 34.4 kDa antigen which was immunogenic when probed IgA, IgM and IgG of *A. baumannii* sera but did not cross reacted with sera from other nosocomial infections and normal controls. This was confirmed by repeated testing.

The 2 sera (AB-009 and AB-012) from *A. baumannii* infection showed 19 and 16 positive bands respectively of which 4 bands were recognized by both the sera. These 4 protein bands were checked for cross reactivity using sera from patients infected with *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Escherichia coli* or normal controls. The three proteins other than the 34.4 kDa protein cross reacted with sera from other nosocomial infections or normal controls. The 34.4 kDa antigen did not show any cross reaction with sera from other nosocomial infections and normal controls suggesting that this protein was specific for *A. baumannii*. This was confirmed by repeated testing.

Studies were also done to:

(i) assess the effect of temperature (41°C identical to the temperature in patients with fever during nosocomial infection) on the expression of the OMPs; (ii) determine the location of the protein by SDS-PAGE analysis of the OMPs. Surface associated proteins
(SAPs) and inner membrane proteins (IMPs) of \textit{A. baumannii} in order to identify the location of the protein.

The protein OMPs profile expressed at 41°C showed a number of few proteins were over-expressed OMPs to be increased in expression (17.3, 22.4 and 60.5 kDa) while some proteins also showed were down-regulated. It is suggested that the higher elevated body temperature of the body during \textit{A. baumannii} infection influences the expression of the bacterial proteins for survival of this bacterium, probably as a mechanism of survival at higher temperatures and also for resistance against drugs to ensure its survival and growth in the body.

The 34.4 kDa antigen was present in all the clinical isolates and hence can be considered as a specific biomarker with great potential as a diagnostic marker. However, the effect of temperature was not uniform in the clinical isolates studied showing increased expression of this protein in 60% of isolates and the down regulation or no effect in 40% of the clinical isolates. This suggests that this protein may not have a strong protective role to play and hence may not be suitable as a vaccine candidate.

It was found that further characterization of the 34.4 kDa protein demonstrated that it was associated with both OMPs and SAPs of \textit{A. baumannii} and is. Besides this, the protein was also analysed for its glycosylation status using glycoprotein staining and also for the main constituents using trypsin digestion. Results showed that it was not a glycoprotein, its main constituents being protein. The 34.4 kDa antigen was present in all the clinical isolates of \textit{A. baumannii}. The expression of this protein was enhanced in
most cases suggesting that this protein could also be related to the virulence of the bacteria. To date, no previous report is available with reference to this specific protein for *A. baumannii*.

Overall, the results of this study has identified a unique protein expressed by the *A. baumannii* clinical isolates which is specific to *A. baumannii* and does not cross react with other bacterial species responsible for nosocomial infections. Western blot analysis showed the protein to be antigenic and induce antibodies. Chemical characterization showed that its main constituent is protein and is not glycosylated.

The results are encouraging in that the 34.4 kDa protein identified is specific for *A. baumannii* and can be used as a biomarker for development of a diagnostic test which would be faster and more specific than the current techniques of diagnosis. However, further studies need to be done to measure the antibody level against this specific protein, the sensitivity and specificity of the protein and the retention time of the antibody detectable in the serum of the infected patients. Since routine culture methods to identify the bacterial infection are laborious, time consuming, relatively expensive and low sensitivity, the development of a more rapid and simplified diagnostic test of *Acinetobacter* infection is highly desirable. The test must be sensitive, specific, and easy to perform, cost effective and be able to detect the presence of *A. baumannii* directly from patients’ blood. As such the objective of the study was to determine the presence of a specific and antigenic outer membrane protein (OMPs) of *A. baumannii*, which can be used for the development of a rapid diagnostic test. Proteins profiles were obtained by...
applying the techniques of sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis was done to detect the presence of IgM, IgA and IgG. All sera from patients infected with *A. baumannii* were collected from the Department of Medical Microbiology & Parasitology, School of Medical Sciences, USM. By the method of elimination, antigenic protein band with a molecular weight of 34.4 kDa, which was uniquely seen only by *A. baumannii* sera and do not cross react with other sera tested was identified. This protein was shown to be antigenic when probed with anti human IgM, IgA and IgG by using patients sera infected with *A. baumannii*. Moreover, it was found to be specific for *A. baumannii* and did not cross react with other sera that causing nosocomial infections (*Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Escherichia coli* etc), most commonly found in hospital Universiti Sains Malaysia (HUSM). Study was also done to determine the location of the protein as to whether it is present on outer membrane only or present in other membranes (surface or inner membrane). It was found that this band was exist in surface associated protein. Besides this, the protein was also analysed for its glycosylation status using glycoprotein staining and also for the main constituents using trypsin digestion. Results showed that it as not a glycoprotein, its main constituents were protein. To date, no previous report has been made regarding the protein. However, further studies --------
CHAPTER ONE

INTRODUCTION

1.0 Introduction

Acinetobacter baumannii is a Gram-negative, non-motile, obligate aerobic cocci that is commonly found in soil, water and sewage, and in healthcare settings (Baumann et al., 1968; Juni, 1978; Dijkshoorn et al., 2007; Perez et al., 2007; Shih et al., 2008). Difficulties in containing, controlling and eliminating the spread of A. baumannii have are challenges faced by clinicians and healthcare providers (Bergogne-Berezin and Towner, 1996; Bernards et al., 2004; Koulenti and Rello, 2006). A. baumannii has emerged as an important and problematic human pathogen as it is the causative agent of several types of infections including pneumonia, meningitis, sepsis, and urinary tract infections. Recently, a drug-resistant A. baumannii was responsible for an outbreak of bacteraemia in more than 240 American troops in Iraq (Centers for Disease Control and Prevention, 2004; Abbott-Davis et al., 2005; Scott et al., 2007), and there is significant concern of a major epidemic involving this organism.

This versatile organism can utilize a variety of carbon sources and is able to grow in a wide range of temperatures (28-53°C) and pH conditions (Yavankar et al., 2007). Lascola and Raoult (2004) isolated A. baumannii from human body lice and speculated that the bacteria may utilize the arthropod host as a one-way means of transmission. This hardiness, combined with its intrinsic resistance to many antimicrobial agents, contributes to the organism’s fitness and has enabled it to thrive in hospital settings.
worldwide. Mortality in patients suffering from *A. baumannii* infections can be as high as 75% (Chastre and Trouillet, 2000).

Alarmingly, little is known about the virulence, antibiotic resistance, or persistent strategies of *A. baumannii*. The pathogenic determinants that have been reported thus far for *A. baumannii* include a novel pilus assembly system involved in biofilm formation (Tomaras *et al.* 2003), an outer membrane protein (Omp38) that causes apoptosis in human epithelial cells (Choi *et al.* 2005), and a polycistronic siderophore-mediated iron-acquisition system conserved between *A. baumannii* and *Vibrio anguillarum* (Dorsey *et al.* 2003, 2004). This presumably comprises a small fraction of elements involved in *A. baumannii* pathogenesis, and thus, novel global approaches are essential to comprehensively understand the basic features of this organism in order to ultimately control the spread of *A. baumannii* infections and to develop effective counter measures against this harmful pathogen.
control the spread of \textit{A. baumannii} infections and to develop effective countermeasures against this harmful pathogen.

\textit{A. baumannii} has been stealthily gaining ground as an agent of serious nosocomial and community-acquired infection. Historically, \textit{Acinetobacter} spp. have been associated with opportunistic infections that were rare and of modest severity; the last two decades have seen an increase in both the incidence and seriousness of \textit{A. baumannii} infection, with the main targets being patients in intensive-care units. Although this organism appears to have a predilection for the most vulnerable patients, community-acquired \textit{A. baumannii} infection is an increasing cause for concern \cite{Chastre et al., 2000}. The increase in \textit{A. baumannii} infections has paralleled the alarming development of resistance it has demonstrated. The persistence of this organism in healthcare facilities, its inherent hardiness and its resistance to antibiotics results in it being a formidable emerging pathogen.

1.1 History and significance of \textit{Acinetobacter baumannii} infection

1.1.1 Epidemiology

\textit{A. baumannii} \textit{Acinetobacter baumannii} has emerged worldwide as an important nosocomial pathogen, causing outbreaks particularly in intensive care units, in wards with patients who have serious underlying illness \cite{Dijkshoorn et al., 2007}. It is responsible for 2\% to 10\% of all Gram-negative bacterial infections in intensive care units in Europe and the United States \cite{Herve Richet and Pierre Edouard Fournier, 2006}. Imipenem is among the drugs of choice for treatment of nosocomial infections due to multidrug-resistant (MDR) \textit{A. baumannii} isolates. However, their efficacy is being
increasingly compromised by the emergence of carbapenem-hydrolyzing β-lactamases of molecular Ambler class B (VIM, IMP) and class D (OXA-23, OXA-58) (Poirel et al., 2005; Coelho et al., 2006; Zong et al., 2008).

A. baumannii has emerged as a highly troublesome pathogen for many institutions globally. Multi-drug resistant A. baumannii (the organism MDRAB) has always been inherently resistant to multiple antibiotics. Multi-drug resistant A. baumannii is abbreviated as MDRAB. Imipenem is among the drugs of choice for treatment of nosocomial infections due to MDRAB strains. However, their efficacy is being increasingly compromised by the emergence of carbapenem-hydrolyzing β-lactamases of molecular Ambler class B (VIM, IMP) and class D (OXA-23, OXA-58) (Poirel et al., 2005; Coelho et al., 2006; Zong et al., 2008). As a consequence of its immense ability to acquire or up-regulate antibiotic drug resistance determinants, it has justifiably been propelled to the forefront of scientific attention. Apart from its predilection for the seriously ill within intensive care units, A. baumannii has more recently caused a range of infectious syndromes in military personnel injured in the Iraq and Afghanistan conflicts (described earlier Scott et al., 2007).

**In conclusion**, the available evidence suggests that A. baumannii is an important human pathogen that is gradually gaining more attention as a public health threat. It
causes a significant proportion of infections in specific patient populations, especially in critically-ill patients receiving care in the ICU setting (Zaragoza et al., 2003; Lee et al., 2004; Longo et al., 2007). This situation, together with the fact that *A. baumannii* isolates have inherent and/or easily acquired mechanisms of resistance against many of the available antimicrobial agents, makes this pathogen one of the most significant microbial challenges of the current era. More scientific efforts and resources are urgently needed to further elucidate the epidemiological and infection control issues related to *A. baumannii* infections, and to investigate treatment options for patients with multidrug- or pandrug-resistant infections.

### 1.1.2 Classification/Taxonomy

In 1980s, *Acinetobacter* was first considered as an emergence of nosocomial pathogens. Members of the genus *Acinetobacter* have a long story of taxonomic change. This confusion makes it difficult to interpret the older medical and scientific literature (Bergogne-Berezin and Towner, 1996). Bergey’s Manual of Systematic Bacteriology classified the genus *Acinetobacter* in the family *Neisseriaceae*, but this arrangement has never been formally approved by the taxonomists. After that, taxonomic developments have resulted in the proposal that members of the genus should be classified in the new family *Moraxellaceae*. This genus, *Acinetobacter*, which is now defined as *Gram* negative (but sometimes difficult to destain) coccobacilli, with a DNA G + C content of 39 to 47 mol%, that are strictly aerobic, non-motile, catalase-positive, and oxidase-negative
(Bergogne-Berezin and Towner, 1996). So far 17 named species have been recognized and 15 genomic species (gen.sp.) have been delineated by DNA–DNA hybridization, which do not yet have valid names (Dijkshoorn et al., 2007).

1.1.3 Properties of Acinetobacter baumannii

1.1.3.1 Physical characteristics

Acinetobacter baumannii does not have fastidious growth requirements and is able to grow at various temperatures and pH conditions (Bergogne-Berezin et al., 1996). The versatile organism exploits a variety of both carbon and energy sources. These properties explain the ability of Acinetobacter species to persist in either moist or dry conditions in the hospital environment, thereby contributing to transmission (Smith et al., 2007). This hardiness, combined with its intrinsic resistance to many antimicrobial agents, contributes to the organism’s virulence and has enabled it to spread in the hospital setting (Abbo et al., 2005). Clinical isolates of A. baumannii are capable of activating N-acylhomoserine-lactone biosensors with maximal activity in the stationary growth phase (Joly-Guillou et al., 2005). Acinetobacters are renowned for their ability to survive in the environment in dry conditions for prolonged periods, and environmental contamination represents an important reservoir for their dissemination (Aygun et al., 2002). Another interesting feature of the catabolic capacity of A. baumannii is its inability to catabolize glucose. Recent report showed that this deficiency in A. baumannii is due to the absence of hexokinase, glucokinase, or any other comparable enzyme that can transfer phosphate onto glucose. Thus, the first step of glycolysis...
cannot be completed (Smith et al., 2007).

1.1.3.2 Growth and cultural characteristics

*Acinetobacter* grows rapidly on 5% sheep blood and MacConkey agars. Characteristic of colonies on 5% sheep blood agar producing smooth, opaque colonies, in which some isolates are β-haemolytic. Colonies on MacConkey agar are light lavender colour indicating but do not non-lactose fermenting colonies lactose.

1.1.3.3 Biochemical characteristics

*Acinetobacter A. baumannii* is an oxidase-negative, catalase-positive and urease-positive bacterium. It shows no reaction with indole and methyl red. In the Triple Sugar Reaction-Iron (TSI) agar, it shows alkaline slant and neutral butt and it does not produce gas (H2S).

1.1.3.4 Physiology and Morphology
Members of the genus *Acinetobacter* are non-motile coccobacilli that are frequently confused with *Neisseria*, in Gram stained samples. They are generally encapsulated, oxidase negative, catalase positive, obligate aerobic and they do not ferment carbohydrates. *Acinetobacter* spp. are short, plump, Gram negative (but sometimes difficult to destain) rods, typically 1.0 to 1.5 \( \mu m \) by 1.5 to 2.5 \( \mu m \) in size during the logarithmic phase of growth but often becoming more coccoid in the stationary phase (Bergogne-Berezin and Towner, 1996).

### 1.2 Clinical significance of *Acinetobacter baumannii*

*Acinetobacter. A. baumannii* is an important nosocomial pathogen that has been implicated in various ranges of infections that mainly affect critically ill patients in ICUs. Hospital-acquired infections caused by *A. baumannii* includes bloodstream infections, ventilator-associated pneumonia, skin and soft-tissue infections, wound infections, respiratory and urinary-tract infections, endocarditis, secondary meningitis etc and other infections (Joly-Guillou *et al.*, 2005; Lee *et al.*, 2006; Dijkshoorn *et al.*, 2007; Lee *et al.*, 2008). These infections are mainly attributed to *A. baumannii*, although gen.sp. 3 and gen.sp. 13TU have also been implicated (Dijkshoorn *et al.*, 2007).

Nosocomial infections that are caused by other *Acinetobacter* species, such as *A. johnsonii, A. junii, A. lwoffii*, etc. are rare and are mainly restricted to catheter related bloodstream infections (Delrieu-Tega *et al.*, 2007). These infections cause minimal mortality and their clinical course is usually benign, although life-threatening sepsis has been observed occasionally (Linde *et al.*, 2002). The most frequent clinical manifestations of nosocomial *A. baumannii* infection are ventilator-associated pneumonia and bloodstream infection, both of which are associated with considerable
morbidity and mortality, which can be as high as 30% to 52% (Seifert et al., 1995; Cisneros et al., 2002; Wisplinghoff et al., 2004).

Recently, bacteraemia caused by *A. baumannii* is one of the infections with the highest mortality rate in hospitals (Joly-Guillou et al., 2005). A survey by the Health Protection Agency in England found that patients with *Acinetobacter* bacteraemia were generally aged > 50 years, that the majority of the patients were male, and that 5% of the patients were hospitalized in general wards and 54% were in ICUs (Wisplinghoff et al., 2000). Risk-factors have been defined in many studies, and are essentially the same as those identified for other opportunistic bacteria (Lee et al., 2004; Falagas et al., 2006; Baran et al., 2008; Shih et al., 2008; Baran et al., 2008). Another study reported that sepsis and/or septic shock in 19% of patients with bacteraemia were caused by *A. baumannii* (Valero et al., 2001). This observation also highlighted the true pathogenicity of *A. baumannii* strains, with a crude mortality rate of 42%.

The infection rate of *A. baumannii* in Hospital USM (HUSM) intensive care unit was shown to be higher than the one reported (19%) from Hospital UKM (another teaching hospital in Malaysia) by Rozaidi et al., 2002. In our current study, we found that the prevalence of *A. baumannii* infection in Hospital Universiti Sains Malaysia (HUSM) is varying from year to year, and the overall prevalence of *Acinetobacter* infection in intensive care units was 12.65%. In 2005, 2006, 2007 and 2008 (up-to June)
the prevalence rate was 18.92%, 29.89%, 26.42% and 26.01% respectively (Data collected from Infection Control Unit, HUSM). The prevalence of A. baumannii infection in intensive care units (General ICU, Neurosurgical ICU and Neonatal ICU) was higher compared to the general ward. The overall prevalence of Acinetobacter infection in intensive care units was 12.65%.

1.2.1 Pathogenesis

A recent study (Smith et al., 2007) has revealed that a large portion of the genome of A. baumannii consists of pathogenicity islands (PAIs). PAIs contain genes implicated in virulence, of which the largest appears to contain a type IV secretion apparatus. Type IV secretion systems have been shown to play an important role in other human pathogens, including Bordetella pertussis, Legionella pneumophila, Brucella spp. and Helicobacter pylori (Schmidt & Hensel, 2004). In the case of A. baumannii, this may be more important, as PAI genes, like other virulence genes, respond to environmental stimuli and thus may only be expressed under stressful conditions.

Smith et al. (2007) also compared the genome sequence of A. baumannii with that of its closest sequenced relative, the non-pathogenic A. baylyi, using the Artemis Comparison Tool (ACT) to identify A. baumannii virulence genes. They found that the most interesting differences between these two organisms lies in the 28 PAIs identified in A. baumannii. Many of the drug-resistance and potential virulence factors found in the A. baumannii genome reside on these islands, indicating that a large number of them are important factor for the pathogenesis of A. baumannii. This presumably comprises a small fraction of elements involved in A. baumannii pathogenesis, and thus,
novel global approaches are essential to comprehensively understand the basic features of this organism in order to ultimately control the spread of *A. baumannii* infections and to develop effective counter-measures against this harmful pathogen.

Clinical isolate of *A. baumannii* is able to survive on abiotic surfaces (plastic or glass surfaces) and produce biofilm, a property that is most likely to be associated with the capacity of this pathogen to survive in hospital environments and medical devices, and cause severe infections in compromised patients (Tomaras *et al.*, 2003). Recently, there was another study performed in Korea that showed *A. baumannii* has significant correlation with epithelial cell adherence because of the ability to form biofilm (Lee *et al.*, 2008). This is because cells growing in biofilms are highly resistant to the components of the human immune system and to numerous types of antimicrobial agents. The study also revealed that *A. baumannii* isolates carrying blaPER-1 showed a significantly higher capacity for epithelial cell adherence and biofilm formation when compared with *A. baumannii* isolates without blaPER-1 (Lee *et al.*, 2008, Loefhelm *et al.*, 2008).

Being a human pathogen, *A. baumannii* must be able to utilize host resources in order to survive. Iron is an important resource that is not readily available in the human host; rather, it is found complexed with iron binding molecules such as heme, lactoferrin, and transferrin. Bacteria survive and multiply under iron-limiting conditions, such as those found in natural and host environments, by expressing active systems that gather this essential micronutrient (Echenique *et al.*, 2001). A study was also performed
to check the iron uptake components of clinical isolates of *A. baumannii* showed that most of the clinical isolates contain *fatA*-like gene. This gene, which is potentially involved in iron acquisition, can be located in different genomic regions for different *A. baumannii* isolates. Disruption of the *fatA*-like gene indeed impairs the iron acquisition phenotype of this strain, hence confirming its role in iron transport (Dorsey *et al.*, 2003).

The pathogenic determinants that have been reported so far for *A. baumannii* include a novel pilus assembly system involved in biofilm formation (Lee *et al.*, 2008; Tomaras *et al.*, 2003), an outer membrane protein (Omp38) that causes apoptosis in human epithelial cells (Choi *et al.*, 2005), and a polycistronic siderophore-mediated iron-acquisition system conserved between *A. baumannii* and *Vibrio anguillarum* (Dorsey *et al.*, 2003, Dorsey *et al.*, 2004).

### 1.2.4.2 Virulence factors

Although *Acinetobacter baumannii* are considered to be relatively low-grade pathogens, certain characteristics of these organisms may enhance the virulence of strains involved in infections. These characteristics include: the presence of a polysaccharide capsule, formed by L-rahmnose, D-glucose, D-glucuronic acid, and D-mannose, which probably render the surface of strains more hydrophilic, although hydrophobicity may be higher in strains isolated from catheters or tracheal devices (Joly-Guillou *et al.*, 2005). The property of adhesion to human epithelial cells in the presence of fimbiiae and/or capsular polysaccharides. The production of enzymes which may damage tissue lipids and the potentially toxic role of the lipopolysaccharide component of the cell wall and the presence of lipid A.
Nosocomial *A. baumannii* bacteraemia may cause severe clinical disease that is associated with a high mortality rate of up to 17% to 25% (Cisneros *et al.*, 1996; 2002). This opportunistic pathogen causes a wide variety of serious infections in humans, mostly in compromised patients. Recently, *A. baumannii* has emerged as an important pathogen among wounded soldiers, threatening civilian and military patients (Davis *et al.*, 2005; Scott *et al.*, 2007; Niu *et al.*, 2008). This opportunistic pathogen expresses a myriad of factors that could play a role in human pathogenesis. Among these factors are the attachment to and persistence on solid surfaces, the acquisition of essential nutrients such as iron, the adhesion to epithelial cells and their subsequent killing by apoptosis, and the production and/or secretion of enzymes and toxic products that damage host tissues. However, very little is known about the molecular nature of most of these processes and almost nothing has been shown with regard to their role in bacterial virulence and the pathogenesis of serious infectious diseases. Fortunately, some of these gaps can now be filled by testing appropriate isogenic derivatives in relevant animal models that mimic the infections in humans, particularly the outcome of deadly pneumonia. Such an approach should provide new and relevant information on the virulence traits of this normally underestimated bacterial human pathogen.

*A. baumannii* infections probably involve numerous factors, including virulence determinants, which have yet to be investigated. *A. baumannii* began to spread rapidly among patients in intensive care units (ICUs) in the 1980s. But studies on *Acinetobacter* virulence factors are still at an elementary stage. Non-specific adherence factors, such as fimbriae, which help adherence to human gastric epithelial cells via adhesions, have
been described in *A. baumannii* (Lee *et al.*, 2006). It is known that, under iron-deficient conditions, bacterial growth can be accompanied by the production of receptors and iron-regulated catechol siderophores, which will, in turn, favour bacterial growth and the expression of virulence factors (Goel *et al.*, 2001).

*Acinetobacter* also can trigger gastritis including hypergastrinaemia and stimulation of cytokine release by the expression of virulence factors (Rathinavelu *et al.*, 2003). Another neuropathological studies have demonstrated that amino-acid sequence homology exists between a bovine prion sequence (RPVDQ) and an enzyme produced by *Acinetobacter*, uridine diphosphate-N-acetylglucosamine-1-carboxyvinyl transferase, which also contains the RPVDQ sequence and could be potentially cross-reactive. As a consequence, an antibody response to the *Acinetobacter* sequence could influence the pathology of the disease (Wilson *et al.*, 2004).

Approximately 30% of *Acinetobacter* strains produce exopolysaccharide, which is a major virulence factor and is thought to protect bacteria from host defences resulting in cytotoxicity for phagocytic cells (Joly-Guillou *et al.*, 2005). In experimental studies, exopolysaccharide-producing strains of *Acinetobacter* have been shown to be more pathogenic than non-exopolysaccharide-producing strains, especially in polymicrobial infections with other species of higher virulence.

Quorum-sensing is another widespread regulatory mechanism among *A. baumannii* which is required for the later stages of biofilm maturation. At present, the
only known determinants required for biofilm formation in \textit{A. baumannii} are the \textit{csu}-encoded chaperone-usher pilus assembly system (Tomaras \textit{et al.}, 2003) and the Bap protein (Loehfelm \textit{et al.}, 2008). Recently another study showed that the \textit{abal}-directed quorum-sensing pathway is required for the later stages of biofilm maturation (Niu \textit{et al.}, 2008). Quorum-sensing might be a central mechanism for autoinduction of multiple virulence factors in an opportunistic pathogen such as \textit{A. baumannii}, and this process should be studied for its clinical implications (Joly-Guillou \textit{et al.}, 2005).

1.2.3 Risk factors

\textit{Acinetobacter A. baumannii} is an important cause of nosocomial infections in many hospitals, which is difficult to both control and treat because of its prolonged environmental survival and its ability to develop resistance to multiple antimicrobial agents (Bergogne-Berezin \textit{et al.}, 1996; Cisneros \textit{et al.}, 2005; Yu-Chen Tseng \textit{et al.}, 2007, Cisneros \textit{et al.}, 2005; Bergogne-Berezin \textit{et al.}, 1996). \textit{A. baumannii} appears to have a propensity for developing antimicrobial resistance extremely rapidly. Moreover, this resistance is multiple, causing serious therapeutic problems (Cisneros \textit{et al.}, 2002). Several studies were conducted to find the risk factors as bacteraemia caused by multidrug-resistant \textit{A. baumannii} (MDRAB) leads to higher mortality and medical cost compared with non-MDRAB bacteraemia. Risk factors may vary between areas with endemic colonization and epidemic outbreaks of infection (Rello \textit{et al.}, 1999; Garcia-Garmendia \textit{et al.}, 2001; Mu-Jen Shih \textit{et al.}, 2008). From the previous studies of risk factors, it was found that longer duration of hospital stay until \textit{A. baumannii} isolation, ICU admission, emergent surgical
operation, total parenteral nutrition, invasive procedures such as central venous catheter, endotracheal tube, urinary catheter, or nasogastric tube, previous administration of carbapenems and previous exposure to broad-spectrum antibiotics have been identified as risk factors for acquisition of A. baumannii in numerous studies were significant risk factors for A. baumannii infections (Garcia-Garmendia et al., 2001; Joly-Guillou et al., 2005; Gulseren-Baran et al., 2008; Joly-Guillou et al., 2005; Garcia-Garmendia et al., 2001).

The risk factors that predispose individuals to the acquisition of and infection with A. baumannii are similar to those that have been identified for other MDR—multi-drug resistant organisms. Risk factors that are specific for a particular setting have also been identified, such as the hydrotherapy that is used to treat burn patients and the pulsatile lavage treatment that is used for wound treatment (Maragakis et al., 2004; Wisplinghoff et al., 1999; Maragakis et al., 2004). The most frequent clinical manifestations of nosocomial A. baumannii infection are ventilator-associated pneumonia and bloodstream infection, both of which are associated with considerable morbidity and mortality, which can be as high as 52% (Seifert et al., 1995; Cisneros et al., 2002; Seifert et al., 1995).

1.2.46 Prevalence

The prevalence of nosocomial bloodstream infections due to Acinetobacter A. baumannii currently has become a public health problem in many countries ranges ranging from 2% to 10% of all gram-negative bacterial infections in Europe (Hanberger et al., 1999) and account for about 2.5% of them in the United States (Jones et al.,
The incidence of severe infection caused by *Acinetobacter* species has been increasing. For example, National Nosocomial Infection Survey data for US intensive care units indicate that *Acinetobacter* species caused 6.9% of hospital-acquired pneumonia in 2003, compared with 1.4% in 1975. The rates of bloodstream infection, surgical site infection, and urinary tract infection have also increased during this period (from 1.8% to 2.4%, 0.5% to 2.1%, and 0.6% to 1.6%, respectively (Gaynes et al., 2005).

*A. baumannii* exhibits a remarkable ability to rapidly develop antibiotic resistance that led to multidrug resistance (MDR) within a few decades (Bergogne Berezin et al., 1996). To date, some strains of *A. baumannii* have become resistant to almost all currently available antibacterial agents (Van Looveren et al., 2004), mostly through the acquisition of plasmids (Joshi et al., 2003), transposons (Smith et al., 2007), or integrons carrying clusters of genes encoding resistance to several antibiotic families (Segal et al., 2003; Poirel et al., 2003) at once.

### 1.2.5 Antimicrobial susceptibility and resistant mechanisms

*Acinetobacter* __*baumannii* is attracting much attention owing to the increase in antimicrobial resistance and occurrence of strains that are resistant to virtually all available drugs (Perez et al., 2007). This organism is generally intrinsically resistant to a number of commonly used antibiotics, including aminopenicillins, first and second generation cephalosporins and chloramphenicol (Vila et al., 1993; Seifert et al., 1995).
It also has a remarkable capacity to acquire mechanisms that confer resistance to broad-spectrum-lactams, aminoglycosides, fluoroquinolones and tetracyclines. *A. baumannii* exhibits a remarkable ability to rapidly develop antibiotic resistance that led to multidrug resistance within a few decades (Bergogne Berezin *et al.*, 1996). To date, some strains of *A. baumannii* have become resistant to almost all currently available antibacterial agents (Looveren *et al.*, 2004), mostly through the acquisition of plasmids (Joshi *et al.*, 2003), transposons (Smith *et al.*, 2007), or integrons carrying clusters of genes encoding resistance to several antibiotic families (Segal *et al.*, 2003; Poirel *et al.*, 2003). Numerous studies have suggested an upward trend in strains of *A. baumannii* that are resistant to these agents. However, because of the scarcity of large-scale surveillance studies from the 1970s to the 1990s and the difficulties in comparing local reports, such trends are difficult to quantify on a global level. Resistance rates can vary according to the country and the individual hospital, and depend on biological, epidemiological or methodical factors (Seifert–Wisplinghoff *et al.*, 2007). Recently, resistance to polymyxins and tigecycline has also been described, which indicates that *A. baumannii* can cause infections that are fully refractory to the currently available antimicrobial drugs (Li *et al.*, 2006; Peleg *et al.*, 2007).

The resistance of *A. baumannii* to antimicrobial agents is mediated by all of the major resistance mechanisms that are known to occur in bacteria, including modification of target sites, enzymatic inactivation, active efflux and decreased influx of drugs (Poirel *et al.*, 2003). Beta-lactamases are the most diverse group of enzymes that are associated...
with resistance, and more than 50 different enzymes, or their allelic forms, have been identified so far in *A. baumannii* (Dijkshoorn *et al.*, 2007). In a previous study, *aac(6’)-Ib* and *aac(6’)-Ih* have been identified as the most prevalent plasmid-mediated *aac(6’)-I* genes among *A. baumannii* strains through which aminoglycoside resistance can be attributed to at least nine distinct modifying enzymes with different combinations in some strains (Doi *et al.*, 2004). In another study reported that resistance to tetracyclines has been associated with *tet (A)* and *tet (B)* genes that encode tetracycline-specific efflux pumps (Huys *et al.*, 2005). ISAba1 is thought to have a key role in some carbapenem-resistant strains by enhancing the expression of the intrinsic OXA-51-like carbapenemases (Turton *et al.*, 2006). Another chromosomal system that is typically found in *A. baumannii* is the AdeABC efflux system (Magnet *et al.*, 2001). Reduced susceptibility to carbapenems has also been associated with the modification of penicillin-binding proteins and porins or with upregulation of the AdeABC efflux system, which might result in high-level carbapenem resistance in *A. baumannii* (Bou *et al.*, 2001). There was another study conducted by Felipe Fernandez-Cuenca and colleagues in 2003 showed that production of β-lactamases of pI 6.3 and 7.0 and reduced expression of PBP 2 (penicillin-binding protein B2) of B2 are the most frequently observed mechanisms of resistance to carbapenems (Fernandez-Cuenca *et al.*, 2003).
Recently, according to the infectious disease society of America (IDSA), *A. baumannii* is considered as one of the three increasingly problematic Gram-negative pathogens (Talbot et al., 2008). MDRAB infections are difficult and costly to treat. A study at a public teaching hospital found that the mean total hospital cost of patients who acquired MDRAB was $USD 98,575 higher than that of control patients who had identical burn severity of illness indices (Wilson et al., 2004).

The incidence of severe infection caused by *Acinetobacter* species has been increasing. For example, National Nosocomial Infection Survey data for US intensive care units indicate that *Acinetobacter* species caused 6.9% of cases of hospital-acquired pneumonia in 2003, compared with 1.4% in 1975. The rates of bloodstream infection, surgical-site infection, and urinary tract infection have also increased during this period (from 1.8% to 2.4%, 0.5% to 2.1%, and 0.6% to 1.6%, respectively (Gaynes et al., 2005).

Therapy Treatment of *Acinetobacter* infection has been complicated by increasing resistance due to aminoglycoside-modifying enzymes, ESBLs, carbapenemases, or changes in outer-membrane proteins and penicillin-binding proteins (Gales Levin et al., 2002). In some parts of the United States, many isolates are now resistant to all aminoglycosides, cephalosporins, and fluoroquinolones (Landman et al., 2002). The carbapenems and combinations of a β-lactam with a β-lactamase inhibitor, such as ampicillin-sulbactam, retain useful activity, but resistance rates are increasing (Quale et al., 2003). In a recent study (Talbot, 2008), data shows that for the carbapenems, which have been demonstrated to have the greatest inherent activity against *A. baumannii*, the frequency of resistance have increased by 20%—from 9% to 39%—
The rate of resistance to fluoroquinolones increased from 50% to 73%, and to β-
lactams from 39% to 66% (p < 0.01 for each comparison). These changes in the
epidemiology and resistance rates of *A. baumannii* have led clinicians to adopt
therapeutic options, such as colistimethate sodium (‘colistin’ also known as polymixin
E), the use of which had previously been abandoned in clinical use because of an
unacceptably high rate of renal toxicity (Falagas et al., 2005; Li et al., 2006).

Currently, several studies have tested the *in vitro* activity of tigecycline, a semi-synthetic
tetracycline (glycylcycline) against *A. baumannii* and reported good bacteriostatic
activity (Seifert-Curia et al., 2008). However, current evidence casts doubt on the role
of tigecycline as a treatment for MDR *A. baumannii* infection, with reports showing
of high tigecycline resistance (Navon-Venezia et al., 2007; Peleg et al., 2007; Reid et
al., 2007; Ruzin et al., 2007; Peleg et al., 2007; Navon-Venezia et al., 2007). The
ability of *Acinetobacter* to rapidly acquire resistance to this new glycylcycline
antimicrobial is cause for concern and adds further stimulus for the discovery of newer
antimicrobials with activities against this problematic organism (Peleg et al., 2007).

Recently, there was a study performed in USA to check the activities of tigecycline in
combination with other antimicrobials. However, the safety and tolerability
associated with the elevated dosages for tigecycline were not known (Scheetz et al., 2007).
Because, so far no clinical trial has been performed and the exact
role of tigecycline in therapy of *A. baumannii* infection remains to be defined (Talbot,
2008).
Bloodstream infections with *A. baumannii* are occurring with increasing frequency, resulting in significant morbidity and mortality ranging from 8% to 43% (Scheetz *et al.*, 2007). Therefore, clinicians must resort to empirical combination therapy, which has an unproven utility, and where therapeutic failures and relapses can be anticipated. Recently, BAL 30376 (Basilea Pharmaceutica Ltd, Switzerland), a novel β-lactum/β-lactamase inhibitor combination, represents an interesting potential approach to therapy of *multidrug-resistant A. baumannii (MDRAB)* (Talbot, 2008). However, clinical study has not yet been conducted on this therapy. In conclusion, we can say as noted reported by the IDSA, “*A. baumannii* is a prime example of mismatch between unmet medical needs and the current antimicrobial research and development pipeline”.

1.3 Rationale of the study

*Acinetobacter A. baumannii* appears to have a propensity for developing antimicrobial resistance extremely rapidly (Cisneros *et al.*, 2002). Moreover, resistance involves multiple drugs and causes serious therapeutic problems. The reason that antibiotic resistance leads to adverse outcomes is presumably because of an increased likelihood that antibiotic therapy will be ineffective or suboptimal (Lee *et al.*, 2007). A higher sepsis-related mortality rate among patients with *multidrug-resistant A. baumannii (MDRAB)* bacteraemia, compared with that for patients with *non-multidrug resistant A. baumannii (MDRAB)* bacteraemia is likely associated with a longer delay in the initiation of appropriate therapy. Several studies have described the relationship between receipt of appropriate therapy and a favorable outcome for the patients with nosocomial bloodstream infections (Ibrahim *et al.*, 2000; Zaragoza *et al.*, 2003). Nosocomial bacteraemia due to *MDRAB multidrug-resistant A. baumannii* is associated
with increased medical costs, prolonged hospitalization, and an increased mortality rate.

Major obstacles in controlling this pathogen are the high contagiousness of the disease and the emergence of multi-resistance characteristics to the commonly prescribed antibiotics. As developing antimicrobial resistance to multiple antibiotics causing serious therapeutic problems, it is crucial to develop a rapid method for identifying the bacteria in order to limit and control outbreaks. Immediate identification of the pathogen in clinical samples is critical to ensure proper clinical treatment, management of the patient and for epidemiological investigations. Current laboratory diagnostic method used to diagnose *Acinetobacter* infection relied on the time-consuming growth in culture media, followed by isolation, biochemical and serological identification. The relatively low sensitivity and the difficulty in performing the current diagnostic procedure have called for an alternative diagnostic method for the early identification of the bacteria. A rapid, simple and reliable diagnostic test is highly desired. One such method involves detection of specific antibodies in clinical specimens. There is a need for the development of next generation immunoassay technologies which provide a more rapid, sensitive and portable assays. The *Immunochromatography ICT* technology, which is based on the membrane-based antibody assays, has been shown to be a potential tool for the diagnosis of pathogens (Smits *et al.*, 2003; Lammie *et al.*, 2004). The advantages of the *immunochromatography ICT* test over culture method are rapidity, simplicity, do not require expensive equipment, do not require cold chain for transportation, enhanced sensitivity and specificity for early diagnosis and the test can be performed at the point
of care. However, there is no report on diagnostic applications employing the immunochromatography concept that have been developed for diagnosis of *A. baumannii* infection. A rapid and reliable diagnostic assay would significantly improve effective management of the disease especially among young children and particularly in patients who are critically ill or immunocompromised. To control outbreaks of the infection caused by *A. baumannii* and to prevent further complications, it is often necessary to treat patients with specific antibodies. Antibiotics at the early stage. This is also very important to reduce the morbidity and mortality and the selection of appropriate antibiotics to control the nosocomial infection caused by *A. baumannii*. Current global diagnostic trend is moving towards rapid immunochromatography ICT platform, there is a need to strategically convert to this test to achieve a more rapid laboratory diagnosis. Thus, efforts to be taken to minimize the delay in the administration of appropriate antibiotic therapy are essential, as are techniques to facilitate the earlier identification of drug-resistant organisms like *A. baumannii*.

### 1.4 Objective of the study

Nosocomial bacteraemia due to multidrug resistant *A. baumannii* MDRAB is associated with increased medical costs, prolonged hospitalization, and an increased in mortality rate. Thus, efforts to minimize the delay in the administration of appropriate antibiotic therapy are essential, as are techniques to facilitate the earlier identification of drug-resistant organism like *A. baumannii*. The ability to produce indigenous test for *A. baumannii* that are novel, specific yet cost effective would now provide a huge impact on public health management not only in Malaysia but all over the world. Thus, the main aim of this study is to find and demonstrate the presence of a specific protein